Bioregnum channel feed – Endpoints News

Bioregnum channel feed

What makes Hal Barron tick? Look at the people he’s teaming up with at GSK

6 years ago

Who’s the toughest on drug prices? A game of political one-upmanship is driving the policy debate in Washington

6 years ago

Why would the FDA approve another controversial drug to spur a woman’s libido with these data? And why no expert panel review?

6 years ago

After watching its share price soar on a Bloomberg report and heated rumors, Biohaven stock takes a billion-dollar bath

6 years ago

Turns out, Rudy Tanzi didn't see much of a story about a hidden link between Enbrel and Alzheimer's either

6 years ago

Silicon Valley's most anticipated slide deck just dropped. What does it mean for biopharma's digital teams?

6 years ago

The Washington Post points the finger at Pfizer for staying mum about an Alzheimer’s study. But there’s more to the story than that

6 years ago

Let's talk AI: Top R&D execs tackle where we are and where we're headed with this crucial new technology

6 years ago

Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs

7 years ago

That feeling you get when you hit the finish line, and then set new goals

7 years ago

Ned Sharpless is not playing with the FDA’s gold standard — any more than Scott Gottlieb did

7 years ago

SCOTUS just turned its back on Allergan’s legal maneuver to take a blow at inter partes review. What did you expect?

7 years ago

Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med

7 years ago

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

7 years ago

RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold

7 years ago

How do you replace a rock star like Scott Gottlieb at the FDA? Maybe you can't

7 years ago

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

7 years ago

The antibiotics R&D effort is broken. Here's one market solution that might fix it

7 years ago

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

7 years ago

Allergan and its Mohawk allies pitch their sovereign immunity case to SCOTUS. And the timing couldn't be worse

7 years ago

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

7 years ago

New Year’s Day price hikes on blockbuster drugs set the stage for a big debate

7 years ago

AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing

7 years ago

Freshman lawmakers give J&J CEO Alex Gorsky another unwanted turn in the public spotlight

7 years ago

First page Previous page 8 9 101112 13 14 Next page Last page